The Research Program on Recombinant DNA Technology, Genes, Environment and Health began in 2000 as a collaboration of research scientists. The collaborating program conducts research on genetic and environmental influences on a wide variety of health conditions and diseases.  The program began with a survey of close to 2 million adult which 600,000 completed the survey, providing data on demographics, health behavior and health history. The program built a secure database with relevant health and environmental information.

Recombinant DNA technology has been effectively used to produce various human proteins in microorganisms, such as insulin and growth hormone, used in the treatment of diseases.

The program will involve the manufacturing of recombinant human insulin which is manufactured in different doses for therapeutic action (insulin lispro, insulin as part, insulin glargine, with very fast, long-acting, respectively) and for different modes of administration.

The research program on Recombinant DNA Technology is planning, it’s second phase to address engagements with national laboratories, hospitals, clinics and municipalities. The program will continue its work as a research program, using large-scale genetic, molecular, environmental and health information developed to enable research on important questions about environment, technology, disease and health.